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Many milestones in medical history rest on animal modeling of human diseases. The SARS-CoV-2 pandemic
has evoked a tremendous investigative effort primarily centered on clinical studies. However, several animal
SARS-CoV-2/COVID-19 models have been developed and pre-clinical findings aimed at supporting clinical
evidence rapidly emerge. In this review, we characterize the existing animal models exposing their relevance
and limitations as well as outline their utility in COVID-19 drug and vaccine development. Concurrently, we
summarize the status of clinical trial research and discuss the novel tactics utilized in the largest multi-center(M.F. Osuchowski).
V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
2 M.S. Winkler et al. / EBioMedicine 66 (2021) 103291trials aiming to accelerate generation of reliable results that may subsequently shape COVID-19 clinical treat-
ment practices. We also highlight areas of improvement for animal studies in order to elevate their transla-
tional utility. In pandemics, to optimize the use of strained resources in a short time-frame, optimizing and
strengthening the synergy between the preclinical and clinical domains is pivotal.








In the era of COVID-19 pandemic, the spreading speed of the
severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2)
and coronavirus disease 2019 (COVID-19) as well as SARS-CoV-2/
COVID-19-related information is unprecedented. The accumulation of
scientific publications eclipses the numbers generated during any
other outbreak in the last 100 years; by March 2021 >110,000
COVID-19-related publications (PubMed) and >14,000 on preprint
health science servers (medRxiv, bioRxiv), e.g., compared to 114,124
all-time PubMed hits for “acute myocardial infarction”. The overall
SARS-CoV-2/COVID-19 clinical information has outpaced data pro-
duced by animal-based studies (about 1:16 ratio in PubMed and 1:7
in medRxi; March 2021). This is understandable given that animal
studies aiming to decipher disease pathophysiology and testing of
experimental therapies typically emerge as a secondary activity. How-
ever, a rapid expansion of preclinical testing capacity may markedly
enhance anti-pandemic strategies, e.g. in a form of negative screening
of potential drug candidates to exclude low-impact compounds and
more efficiently streamline the drug and vaccine development pro-
cesses. Notably, such an expansion contradicts long-term goals set by
various inter(national) policy makers (including the 2019 EU Directive
(2010/63/EU) aiming at radical reduction and elimination of animal
safety & drug testing [1]. Given the investigative burden of the current
pandemic, it appears that animal-based research plays a central sup-
portive role in the quest for quality scientific information. Instead of
its reflexive down-scaling, a concerted effort should be made to
develop routes by which reliable animal-based findings are generated
- accounting both for ethical consideration and emergency needs
such as the current (and imminent future) pandemic(s). Such a quality
pre-clinical knowledge, when efficiently merged with the clinical
domain, may facilitate a more rapid understanding of COVID-19 path-
ophysiology and improve patient care [24]. With this in mind, we
present an overview of current animal and human COVID-19 studies
with the goal of providing information, inspiration, and guidance to
clinical and basic researchers. This review i) provides a detailed over-
view of the current status of both preclinical and clinical studies on
COVID-19, including their strengths and limitations, and ii) aims to
identify important points of synergy between these two research
areas. We further propose a list of priorities that we believe are criti-
cal to the synchronization of preclinical and clinical studies and thus
to a more rapid and effective response to the pandemic.
2. Pre-clinical models and COVID-19 phenotypes
This chapter provides a focused overview of the animal modeling
landscape in the specific context of the animal-to-human research
interaction discussed in the subsequent chapters. Several recent
reviews provide exhaustive species-specific modeling details [5,6]
and a National Institutes of Health (NIH) provide up-to-date informa-
tion on animal COVID-19 models (https://opendata.ncats.nih.gov/
covid19/animal).
Several species were already tested regarding their utility in
reproducing COVID-19 (Table 1). The World Health Organization
(WHO) currently indicates four species as reproducible COVID-19
models: non-human primates (NHP), ferrets, hamsters and mice
(Fig. 1). Except for mice, all indicated species are susceptible as wild-type (WT) and genetic manipulations have not been attempted. WT
mice are resistant to SARS-CoV-2 infection as the viral spike protein
has a minimal affinity to the murine angiotensin converting enzyme-
2 (ACE2) receptor. Approaches utilized to obtain SARS-CoV-2-to-
ACE2 binding in mice are chiefly based on either i) the pathogen or ii)
host’s manipulations. In the first, the SARS-CoV-2 either undergoes a
serial passaging that introduces permissible mutations in the recep-
tor-binding domain (RBD) of S-protein [7,8] or relies on reverse
genetics modifying S-protein RBD to bind the murine ACE2 [9]. From
the host’s perspective, susceptibility to infection is achieved by intro-
duction of human ACE2 gene (hACE2) [5,10]. hACE2 transgene can be
either expressed under a tissue-specific promoter (Krt18 in epithelial
lineage) [11] or a non-specific highly active promoter (e.g. CMV) [12].
Additional strategies include placing the human transgene under a
murine ACE2 promoter [13] or by knock-in of human cDNA in the
locus of murine Ace2 [14,15]. A transient expression of hACE2 in the
murine respiratory tract can be also achieved by transduction of
hACE2 expressing cassette using adenoviral [16,17] or adeno-associ-
ated virus [10]. The transient expression model may facilitate a rapid
humanization in numerus mouse strains providing a powerful tool
for mechanistic studies [5,10].
Apart from ACE2, the newest evidence implicates additional
receptors contributing to the SARS-CoV-2 tropism and cellular entry
(e.g. acting as co-factors) with a potential propensity to specific tis-
sues/cells. For example, neuropilin-1 and CD147 receptor were
shown to be highly expressed in olfactory epithelial cells and brain
[18,19] whereas the expression of tyrosine-protein kinase receptor
UFO (AXL) was high in pulmonary and bronchial epithelial cells [20].
Less experimentally prominent but infection-permissible (also via
airborne route) species include symptomatic (with pneumonia)
minks [21,22] and tree shrews [23,24] as well as asymptomatic cats
[25,26] and rabbits [27]. Dogs [25], pigs [25,28] and poultry [29] are
generally considered SARS-CoV-2-resistant.
2.1. General symptoms and age effect
All WHO-recommended species (also others) robustly shed virus
via the respiratory tract and present with a varying magnitude of
symptoms (synopsis in Table 1). Assessment of clinical COVID-19
symptoms greatly varies among species; in NHP and medium-size
species (e.g. ferrets, cats), human-like respiratory examination end-
points/techniques may be effectively utilized. In small species (ham-
sters, mice), due to technical constraints, such an assessment is
typically less precise and based on non-respiratory parameters (e.g.
asthenia, ruffled fur, hunching, weight loss); methods such as micro-
CT although utilized [30,31] are less common.
NHP including cynomolgus macaques, African green monkeys and
common marmosets recapitulate several features of human COVID-
19 albeit with generally mild symptoms predominating (www.who.
int/publications/m/item/covid-19-animal-models-summary-of-prog
ress-made-by-the-WHO-covid-19-modelling-15-26-march-2020).
Macaques, especially Macaca mulatta appears to be the most suscep-
tible to SARS-CoV-2; they developed COVID-19-like lung lesions
albeit with moderate symptoms [32]. Presently, aged Rhesus maca-
ques [33,34], baboons [35], hamsters [30,36] and mice [79,14]
developed more severe disease (versus young) ranging from weight
loss, exacerbated pneumonia, cellular pulmonary infiltration and
Table 1
Overview of principal pre-clinical models used to investigate COVID-19
Species Susceptibility Recorded
Symptoms













mild-to-moderate yes yes +++ yes Oral/nasal/
rectal swabs, BAL,
feces





 Neutralizing mAb [105,175]
 Catalase [56]













 Lopinavir-ritonavir, HCQ sulfate,
emtricitabine-tenofovir [38]
 TLR2/6 agonist [181]













 Neutralizing mAb [55, 174,
191195]
 Ranitidine bismuth citrate [196]
 Vaccine [62,165,197]









High, Old more susceptible Difficulty breathing
Weight loss
Asthenia
mild-to-lethal* yes yes +++ yes Feces & N/A N/A  Pudilan xiaoyan [49]
 Neutralizing mAb [17,192]







Cat [25,26] High, Young more susceptible Asymptomatic N/A yes N/A ++ Yes Naso-pharynx, nasal wash, serum, feces Yes 6/6 N/A
Dog [25,200,201] Low Asymptomatic N/A no N/A -/+ Yes, in half Feces & N/A No 2/0 N/A
* Mortality recorded in at least five mouse studies [7,15,42,202,203]
# Both infectious and non-infectious viral shedding
& Data as: total number of naive animals exposed/number of naïve SARS-CoV-2 positive animals; animals from all studies per species combined
x NHP include: Rhesus macaques (Macaca mulatta), crab-eating macaques (Macaca fascicularis), baboon (Papio hamadryas), Rivet/African green monkey (Chlorocebus spp.) and common marmoset (Callithrix jacchus). BAL: bron-
choalveolar lavage; BALB/c: BALB/c mouse strain; BT: body temperature; C57BL: C57BL mouse strain; hACE2: human angiotensin converting enzyme-2; HCQ: hydroxychloquine; mAb: monoclonal antibody; mAb: N/A: not avail-










Fig. 1. The current landscape of animal models and their utility in the SARS-CoV-2/COVID-19 pandemic. The figure includes four species currently indicated by the WHO as repro-
ducible COVID-19 models. Vaccines in their developmental phase are commonly tested in Rhesus macaque and mice (shown); infrequently in other species such as hamster and fer-
ret (shown) as well as rat, guinea pig, pig, sheep and others (not shown). A current list of species reported to be used for COVID-19 vaccine and drug development outside of peer-
reviewed press is detailed in an interactive map of the European Animal Research Association (https://public.flourish.studio/visualisation/1698667/). To date (February 2021),
hydroxychloquine, favipiravir and TLR2/6 agonist were the only peer-reviewed therapeutics preventively tested in animals (NHP, ferret, hamster). Lethal COVID-19 phenotype was
reported in three studies employing the mouse model. Aged (but not young) NHP displayed a moderate pneumonia (accompanied by relatively mild clinical symptoms) presenta-
tion after infection with SARS-CoV-2. Ferrets typically displayed mild symptoms accompanied by a matching pneumonia severity. In hamsters, an advanced lung pathology can be
produced but it is concurrent with mild disease symptoms. In all tested species a non-symptomatic phenotype upon infection with SARS-CoV-2 was demonstrated. No animal study
focused on the chronic COVID-19 phenotype and its sequelae has been conducted yet.
NH: non-humane (primate), ARDS: Acute respiratory distress syndrome. The top of each gray bar indicates the maximal severity specific for a given species; all milder pheno-
types, visualized by the gray bar area, can also be produced. The number overlaid on bars depicts an approximate count of the PubMed-listed studies (prevention, vaccination and
disease model) utilizing a given species (PubMed queried on February 18, 2021).
4 M.S. Winkler et al. / EBioMedicine 66 (2021) 103291cytokine release to respiratory dysfunction. Notably, one mouse
study reported hyposmia/anosmia after intranasal SARS-CoV-2 inoc-
ulation [37]. Additionally, aged Rhesus [33] and tree shrews [23] dis-
played prolonged virus shedding whereas viral clearance was
delayed in aged BALB/c mice [9] although the viral loads across
organs were typically age-independent in mice [8,9,14], tree shrews
[23] and higher in aged macaques [33]. Ferrets exhibit upper respira-
tory tract symptoms, fever and distinct lung pathology [25,3840]
resembling those occurring in mildly ill humans. Ferrets also display
a SARS-CoV-2 shedding via multiple routes (for up to 8 days) and are
susceptible to airborne infection (Table 1). Hamsters constitute
another reproducible experimental option (Table 1); the infection
model is stable and pneumonia is evident in the majority of infected
animals. Similarly to ferrets, hamsters display a robust airborne
SARS-CoV-2 transmissibility from infected to naïve animals.
2.2. Severity and lethality
While the majority of SARS-CoV-2 susceptible species display
respiratory symptoms (including COVID-19-like pneumonia), they
generally lack hypoxemic respiratory failure, extrapulmonary organ
dysfunction and lethality (Table 1). Two recent studied reported
advanced (but non-lethal) lung abnormalities by a micro-CT exami-
nation (accompanied by up to 20% weight loss) in SARS-CoV-2-
infected hamsters [30,31], while other hamster-based studies did not
report overtly severe phenotypes and lethality (Table 1). Initially, in
mice infected with SARS-CoV-2, a relatively more severe disease phe-
notype (compared to other laboratory animals) has been reflected by
up to 20% body weight loss but without mortality. Since July 2020, a
lethal phenotype in murine models was reported by at least five stud-
ies (Table 1) that utilized mouse-adapted virus and various forms of
ACE2 receptor humanization to facilitate the SARS-CoV-2-to-ACE2
receptor binding. Further larger studies need to precisely establish
the occurrence and characteristics (e.g. early vs. late mortality) of the
lethal phenotype and its causes (e.g. virus inoculum volume, applica-
tion routes, pulmonary vs. extrapulmonary involvement) in those
emerging mouse-based models. It appears that the general severity
typically increases with age; old (surviving) macaques presentedwith more pronounced pneumonia concurrent with severe pulmo-
nary lesions, inflammation and edema [33,34] and these derange-
ments were also largely recapitulated in aged mice [79,14]. In
hamsters, although the infection model may produce even a severe
lung pathology (shown in aged subjects), mild disease symptoms
predominate. Summarizing, the current evidence suggests that aged
Rhesus macaques and the mice (across different ages) with an
enhanced ability for SARS-CoV-2 binding most closely display the
COVID-19 phenotypes observed in the intensive care unit (ICU)
patients.
3. Current limitations in SARS-CoV-2/COVID-19 animal modeling
Animal COVID-19 models should ideally provide a full recapitula-
tion of COVID-19 pathophysiology represented by an array of the
clinical phenotypes and their sequelae and be widely available. Cur-
rent high demand for experimental animals exceeds capacity of com-
mercial breeders impeding the investigative progress and
verification of the existing findings. The limited lethality across
SARS-CoV-2/COVID-19 models constitutes a critical shortcoming
(Fig, 1, Table 2). To maximize translational value, several key model
design elements need to be contemplated: i) severe COVID-19 phe-
notypes (short and long-term), ii) aged animals as they correspond to
the most commonly affected patient demographic, iii) the most fre-
quent COVID-19-related comorbidities (e.g. diabetes, obesity, cardio-
vascular), iv) sex effects. The lack of those components fail to provide
an adequate clinical outcomes match-up with the most severe
COVID-19 patients. The available models can be relatively easily
enriched by some elements (e.g. both sexes, comorbidities, age) that
will likely induce more severe phenotypes and possibly evoke some
extrapulmonary complications. The existing evidence supports this
notion; SARS-CoV-2-infected mice showed viral replication and
shedding in the brain [14,15,4143], aged NHP [33] and male mice
(also after SARS-CoV) [44] displayed a higher mortality [15] while
female tree shrews demonstrated higher SARS-CoV-2 load in tissues
and swabs [23].
Other shortcomings are difficult and impossible to overcome.
Immuno-modulatory agents against COVID-19 are difficult to
Table 2
Limitations and solutions in animal modeling of SARS-CoV-2/COVID-19
COVID-19 specific modeling limitations: Improvement possible? Possible action(s)
Lack of mortality and/or severe COVID-19 phenotypes yes employing higher viral load/aged animals/comorbidities
remodeling interactions between ACE2-SARS-CoV-2 (e.g. serial passage, reverse genet-
ics)
immuno-suppression induction (constant, transient)
Absence of systemic endotheliitis unclear -“- & using genetically modified animals with propensity for endothelial inflammation &
hypercoagulation
models with chronic endothelial pathology (e.g. atherosclerosis)
Lack of comorbidities* yes including any relevant co-morbidity
rodent ACE2 fail to bind SARS-CoV-2 yes humanizing mouse ACE2, ACE2-SARS-CoV-2 adaptation/remodeling
Limited extra-pulmonary symptoms/derangements unclear higher viral load/aged animals/comorbidities, remodeling interactions between ACE2-
SARS-CoV-2
Non-specific modeling limitations: Improvement possible? Possible action(s)
Limited use of mature/aged animals yes inclusion of aged animals
Limited critical care-like protocols with difficulty advanced ICU-like setups (e.g. ventilation, central lines)
Absence of long-term monitoring yes protracted monitoring in animals with severe phenotypes to test for long-term effects
Lack of comorbidities# yes including any relevant co-morbidity
Anatomical/physiological differences with difficulty confirmatory studies across various species, humanized animals
Interspecies immune systems differences limited expression of human genes, transplantation of human cells
Restrictive legislation for critical care models yes cooperation with ethical and regulatory bodies
* comorbidities including pulmonary illnesses, diabetes, hypertension, obesity that predispose for severe COVID-19 phenotypes, # any other pre-existing conditions and genetic
alterations that are not currently known to predispose/protect against severe COVID-19 phenotypes
M.S. Winkler et al. / EBioMedicine 66 (2021) 103291 5investigate given different inter-species immune responses. To
improve mechanistic understanding, a given therapeutic should pref-
erably be tested in different species. Furthermore, while the availabil-
ity and ease of use of experimental animals are inversely correlated
to their size, the physiological and anatomical similarities are not. For
example, the lethal phenotype and neurological sequelae position
the mouse as a translationally-attractive model for COVID-19. Unfor-
tunately, the mouse is an inferior model of human airway diseases
given its e.g., monopodial (versus human trichotomous) airway
branching system, much smaller alveolar and ventilatory unit diame-
ter, richer bronchus-associated lymphoid tissue and differences in
regenerative pulmonary response [4547]. A reflexive over-reliance
on a single-species disease model may produce misleading findings
that are rapidly propagated until contradicted in other species. This
limitation is aggravated with the rare pre-clinical use of ventilatory
support - the hallmark of severe COVID-19 treatment. While techni-
cally possible, its complexity practically eliminates mechanical venti-
lation from large-scale animal studies [48]. The work with SARS-CoV-
2 virus is further burdened by the enhanced biosafety (BSL-3)
requirements (increasing costs and limiting modeling capacity) and
increasingly restrictive ethical consideration (especially in the EU
countries) regarding the use of animals models at the highest severity
classification [1].4. Animal models to test anti-COVID-19 therapies
The emergence of the first reproducible models that partly reca-
pitulate COVID-19 has enabled limited in-vivo testing. The first study
testing a traditional Chinese medicine in hACE2 mice was published
on May 5, 2020 [49], followed by studies examining the efficacy of
several antivirals, chloroquine (CQ), hydroxychloquine (HCQ), neu-
tralizing monoclonal antibodies (mAb) and convalescent plasma
(Table 1 provides a complete list of treatment studies against SARS-
CoV-2/COVID-19 per listed species). A ferret study demonstrated a
potential utility of emtricitabine-tenofovir in reducing COVID-19
symptoms but inefficacy of lopinavir-ritonavir [38]. Plitidepsin that
undergoes clinical testing (NCT04382066), reduced SARS-CoV-2
infection and COVID-19 lung pathology in mice [50]. While in vivo
findings should be interpreted with caution given the infancy of the
COVID-19 modeling, the emerging data are largely compatible withthe findings from the largest clinical trials. For example, CQ/HCQ
demonstrated neither preventive nor therapeutic benefit in non-crit-
ical pneumonia in NHP [51], ferrets [52] and hamsters [52]. However,
remdesivir demonstrated some potential benefit in NHP [53] and
mice [16,54] and the same holds true for convalescent plasma and
neutralizing monoclonal Abs tested (pre-and post-infection) in mice
[16,17,37] and hamsters [55] (Table 1). Given the current clinical
uncertainty regarding the latter therapeutics, animal data should not
be reflexively dismissed as unreliable but further explored to gain
knowledge why they were successful and utilize this information in
optimization of subsequent human trials including endpoints, cohort
selection, qualitative antibody enrichment, application routes. A
recent pharmacokinetic COVID-19 study demonstrated an advantage
of a nebulization route for nanocapsuled catalase over its systemic
delivery in Rhesus macaque [56]. Pre-clinical evidence rarely trans-
lates 1:1 to clinical evidence; the fidelity of animal studies should not
be judged on the anticipated results but rather the quality of their
unbiased and robust design involving various species.5. Utility of animal models in vaccine development
In February 2021, the WHO reported 63 candidate vaccines in
clinical trials and 179 in preclinical evaluation (https://www.who.int/
publications/m/item/draft-landscape-of-covid-19-candidate-vac
cines). Twenty vaccines entered phase 3 trials and demonstrated
interim benefits have led to regulatory approval/authorization of 10
vaccines https://www.nytimes.com/interactive/2020/science/corona-
virus-vaccine-tracker.html). The development process of COVID-19
vaccines, including some of the most advanced Janssen-Cilag [32],
Sinovac [57], Oxford/AstraZeneca [58], Moderna [59], Pfizer/BioN-
Tech [60] and Sinopharm [61] heavily depended on animal testing
(Table 3). The key pre-clinical step typically involved vaccine efficacy
testing in Rhesus macaques. In four of those studies, immunization
with the vaccine candidates was also performed in BALB/c (Sinovac,
Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm), CD1 mice
(Oxford/AstraZeneca) and in Wistar (Sinovac) and Sprague Dawley
rats (Sinopharm). Rhesus macaques have been generally preferred
given that they become clinically symptomatic following the SARS-
CoV-2 challenge. Although a SARS-CoV-2 infection in young maca-
ques cannot be considered a severe COVID-19 disease model, non-
Table 3
The use of animal SARS-CoV-2 infection models in vaccine development*
Species & strains Intervention Endpoints
Inbred BALB/c mice (1,3,5,6) Immunization with vaccine candidate Antibody titers (1,3,5,6), T- & B-cell counts (5), T-cell responses (3,5). Inflammation & other
(nonspecified) adverse events (1).
Outbred CD1 mice (3) Immunization with vaccine candidate Antibody titers, T-cell responses
Wistar rats (1)
Sprague-Dawley rats (6)
Immunization with vaccine candidate Antibody titers
Inflammation & other (nonspecified) adverse events (6)
Rhesus macaques (1,2,3,4,5,6) Immunization with vaccine candidate
followed by challenge with SARS-CoV-2 (1-6).
Post-immunization effects: Antibody titers (1,2,3,4,5), T-cell counts (1), T-cell responses
(2,3,4,5), plasma cytokines (1,3), BAL immunophenotyping (4), biochemistry (1), histopa-
thology of various organs (1), fever (1), weight loss (1), appetite (1), mental state (1),
non-specific adverse events (3).
Post-challenge effects: viral load in respiratory tract and lungs (16), bronchoalveolar fluid
cytokines (2), BAL immunophenotyping (4), pulmonary histopathology (1,2,3), respira-
tory tract histopathology (3), histopathology of other organs (3), clinical score (3), non-
specified clinical signs of disease (5,6)
1: Sinovac [57]; 2: Moderna [59]; 3: Oxford/AstraZeneca [58] 4: Janssen-Cilag [32]; 5: Pfizer/BioNTech [60]; 6: Sinopharm [61]
BAL: bronchoalveolar lavage
* Studies on vaccine candidates in an advanced stage (regulatory approval granted/pending or phase III trials near completion or completed) are included.
6 M.S. Winkler et al. / EBioMedicine 66 (2021) 103291vaccinated animals developed pulmonary pathology resembling clin-
ical presentation [5759,61]. Of note, the adenovirus vaccine (John-
son & Johnson) tested in Rhesus macaques produced a complete
protection in 17 while partial/non-protecting response in 22 animals
[32]. In hamsters, vaccination attenuated pneumonia and weight loss
post-SARS-CoV-2 infection [62,63]. Furthermore, adapting the SARS-
CoV-2 virus (S-protein RBD remodeling and serial passaging) [8,9]
and genetic modifications (hACE2 mice) [64] aiming at exacerbating
the mouse COVID-19 severity markedly expand the potential for vac-
cine testing.
Previous animal studies alerted to relevant immunopathology
induced by several vaccine candidates against SARS-CoV [65,66] and
research on the Dengue virus vaccine [67] indicated that application
of S-protein specific antibodies can enhance viral replication (so-
called antibody-dependent enhancement; ADE) and skew the macro-
phage response upon SARS-CoV infection in mice and NHP [68,69].
The existing SARS-CoV-2 studies mitigate these concerns; in none of
the tested species, any serious adverse events were observed post-
immunization [57,58]. Moreover, in vaccinated macaques, the SARS-
CoV-2-induced inflammatory response and histopathological
changes were attenuated compared to non-vaccinated controls.
Given the emergency need, it has been postulated by some to omit
animal-based safety testing and to directly transition vaccine candi-
dates to phase-1 trials; some companies have partly followed that
fast-track route [70]. Such an accelerated development, however, is
considered very controversial by many experts [70,71] as it risks
exposing human recipients to: i) potential adverse effects and ii) to
non-toxic but no/low-efficacy vaccines. To increase a possibility of
detecting any adverse effects during the preclinical safety testing, it
is advisable to employ more than a single species.6. Clinical trials in the pandemic
According to registry data (https://covid19.trialstracker.net), the
increase of clinical studies since the onset of the pandemic is unprec-
edented. As of March 2021, there were over 6400 entries on COVID-
19 clinical studies. The following section provides a summary of the
currently active/recruiting phase II-IV trials testing immuno-modu-
lating substances, which subjectively constitute: i) the largest and
most dynamic therapeutic domain, and ii) the most challenging area
for animal-to-patient translation and iii) it remains unclear whether
hypo- or hyperinflammation responses dominate in COVID-19 pro-
gression. The subsequent sections discuss key challenges related to
the design and execution of clinical trials.6.1. Corticosteroids
Four randomized clinical trials (RCTs; including RECOVERY) indi-
cated a potential clinical benefit of intravenous dexamethasone/
hydrocortisone in critical COVID-19 patients [7275]. In the CoDex
study enrolling 299 patients with moderate-to-severe ARDS, intrave-
nous dexamethasone increased ventilator-free days (verum 6.6 days,
control 4.0 days) [74]. However, little is known about potential side-
effects and the benefitrisk profile of corticosteroids across the full
spectrum of COVID-19 patients [76]. Although RECOVERY did not
report adverse events, corticosteroids are potent immunosuppres-
sants which may impair viral clearance [77], increase secondary
infections (fungal, bacterial) and promote metabolic adverse events
[78]. Additionally, targeted corticosteroid delivery via inhalation is
investigated in six ongoing trials (NCT04355637; NCT04416399;
NCT04331470; NCT04377711 & NCT04193878; NCT04330586).
Inhaled corticosteroids (for obstructive pulmonary disease) were
associated with an increased risk of upper respiratory tract infection,
and there is scarce evidence of benefit of inhaled corticosteroids in
COVID-19 [79,80]. Interestingly, asthma patients treated with inhaled
corticosteroids appear to present a reduced sputum cell expression of
ACE-2 and transmembrane protease serine 2 (required for cellular
entry by SARS-CoV-2) [81]. In a recent Korean study, a prior use of
inhaled corticosteroids did not increase COVID-19-related mortality
[82]. Summarizing, time-limited corticosteroid therapy (approx. 10
treatment days) is beneficial in selected critically ill cases. Additional
data on exact timing, dose, administration route, and potential side
effects (e.g. immunosuppression, secondary infections) is required to
optimize the corticosteroid treatment guidelines.6.2. Cytokines, chemokines and their receptors as targets
Multiple trials evaluate modulation of diverse cytokines: either as
application of the recombinant protein, such as granulocyte-macro-
phage colony-stimulating factor (GM-CSF; three trials), interferon
(IFN)-a (one trial), the neutralization of cytokines such as macro-
phage colony-stimulating factor (M-CSF; one trial), interleukin (IL)-6
(nine trials), IL-1b (one trial), tumor necrosis factor (TNF) (one trial),
TNF superfamily member 14 (TNFSF14; one trial), and their receptors
such as GM-CSF receptor (one trial), IL-1Ra (eight trials), and IL-6R
(one trial). Few studies target chemokines e.g. IL-8 (one trial) or che-
mokine receptors, such as CCR5 (six trials). The majority of these tri-
als use humanized antibodies and few trials employ small molecule-
based inhibitors.
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suggested as adjunctive treatment in COVID-19. While smaller stud-
ies provided variable results with anti-IL-6 (siltuximab) and anti-IL-6
receptor (tocilizumab) antibodies [83], the recent REMAP-CAP
showed an improved outcome in the ICU COVID-19 patients treated
with tocilizumab [84] and the newest press release by RECOVERY
trial announced its life-improving efficacy in hospitalized COVID-19
patients (www.recoverytrial.net). Similarly, the off-label use of
recombinant human IL-1Ra (anakinra) in 52 COVID-19 patients was
associated with reduced ICU admission for mechanical ventilation
and death [85]. However, anakinra was not beneficial in mild-to-
moderate COVID-19 [86]. Conversely, the anti-IL-1b antibody canaki-
numab did not influence outcome in 450 COVID-19 patients
(NCT04362813). As anakinra blocks the biological activity of both IL-
1a and IL-1b, whereas canakinumab inhibits only IL-1b, this may
suggest that the effectiveness of anakinra is attributable to the IL-1a
blockade. A multicenter SAVE-MORE anakinra trial stratifying
COVID-19 patients based on the soluble urokinase plasminogen acti-
vator receptor concentration may provide a deeper therapeutic
insight (NCT04680949). Other cytokine targets include TNF (mono-
clonal antibody  infliximab  and a recombinant fusion TNF recep-
tor - etanercept) and IFN-g (emapalumab, a monoclonal antibody).
Baricitinib is a selective Janus kinase (JAK1/JAK2) blocker that inhibits
the gp130 family cytokines (e.g. IL-6,-12,-23 and IFN-g); it can poten-
tially inhibit viral infection of cells by inhibiting kinases involved in
viral endocytosis [87]. GM-CSF is considered a multifaceted contribu-
tor to the COVID-19 pathogenesis with both administration and inhi-
bition currently studied [88]. Summarizing, there have been
numerous attempts to limit the consequences of a “cytokine storm”
(CS) even though it remains unclear whether a CS phenomenon in
COVID-19 truly exists and to what extent it might contribute to the
disease pathophysiology (Lancet RD in press). The variable effects of
anti-IL-6/IL-1 trials underline the need for well-designed cohort-
based studies to pinpoint the potential therapeutic benefit of those
anti-inflammatory approaches.
6.3. Receptor-driven signaling pathways
Several trials target downstream signaling cascades of receptors
of cytokines, chemokines and pathogen recognition receptors: 24 tri-
als test the inhibition of the JAK pathway (Ruxolitinib), six trials of
inhibitors of the Bruton’s tyrosine kinase, two trials of sphingosine
kinase 2 (Opaganib) and one trial inhibition of phosphoinositide 3-
kinase. Two studies target pattern recognition receptors toll like
receptors (TLRs) 2/6/9 and cytosolic NLRP3, the receptor component
of the canonical inflammasome complex. Regarding T-cells, divergent
approaches aim at either boosting the cellular activity with Thymo-
sin-1a (four trials) and anti-program cell death protein (PD)-1 anti-
body (three trials) and inhibiting its activation with cyclosporine (10
trials) and IMU-838 (an inhibitor of dihydroorotatedehydrogenase of
activated lymphocytes; five trials). 71 trials evaluate the application
of recombinant interferons, alone or in combination with other drugs,
with IFN-a (17 trials) and b (33 trials) to boost the T cell activity.
Summarizing, based on the emerging positive results in patients with
a milder COVID-19 [89,90] and evidence on the disturbed interferon
responses in the blood compartiment, interferon-replenishing inter-
ventions appear to belong to the most promising modulators.
6.4. Cell-based therapies
Cell based therapies such as intravenously and intrapulmonarily
delivered mesenchymal stem cells (MSC) have gained interest as a
potential treatment in COVID-19-related lung injury given their anti-
inflammatory and immunoregulatory abilities with possible effects
on the lung tissue repair. Presently, three published phase I trials
investigating MSCs in severe COVID-19 showed promise [9193].These single-site Chinese studies demonstrated that MSC infusion
was safe for up to 28 days. However, due to the study-design limita-
tions the true therapeutic gains cannot be defined.
Overall, 55 clinical trials investigating cell-based therapies are
currently underway (phase I n = 12, phase I/II n = 22, phase II n = 15,
phase II/III n = 5, phase III n = 1), using MSCs of different origins (e.g.,
placental, adipose tissue-derived MSCs) and isolated SARS-CoV-2
specific T cells. Furthermore, native natural killer (NK) cells (4 trials)
and genetically modified NKG2D-ACE2 CAR-NK cells (1 trial) are
tested; both strategies aim at recognizing/inactivating virus-infected
ACE2-expressing cells. To increase efficacy and reduce the cytokine
release syndrome (CRS) risk, those genetically engineered NK-cells
are modified to secrete both GM-CSF neutralizing single-chain vari-
able fragment (scFv) and an IL-15 agonist (sIL-15/IL-15Rɑ chimeric
protein) inhibiting the otherwise short NK-cell survival time. Sum-
marizing, there is no evidence currently supporting the use of cell-
based therapies in COVID-19. To evaluate survival and tissue repair
effects of cell-based therapies in COVID-19, randomized phase 2/3 tri-
als with a long-term follow up and relevant mechanism-of-action
endpoints are required.
6.5. Other immunomodulators
The use of nonsteroidal anti-inflammatory drugs in COVID-19
patients is deliberated [94]. Early therapy with ibuprofen as a cyclo-
oxygenase inhibitor was hypothesized beneficial in preventing dis-
ease progression and reversing lymphocytopenia [95] and a large
trial enrolling patients with mild-to-moderate respiratory failure is
underway (NCT04334629). Intravenous and inhaled iloprost (an
endothelium-protective prostaglandin analogue) are under evalua-
tion in two randomized trials in patients undergoing mechanical ven-
tilation [96]NCT04445246). The anti-complement (C)-5 monoclonal
antibody Eculizumab and the anti-C3 cyclic peptides AMY-101 have
been used in COVID-19 [97] and clinical trials are underway
(NCT04395456; NCT04333420). Moreover, the effects in reducing
lung injury and promoting repair mechanisms of complement C5
inhibitor Zilucoplan is the aim of a small study in COVID-19 patients
with moderate-to-severe ARDS [98]. In another small-scale trial, 28-
day mortality decreased following (C5a-targeting) vilomemlimab
treatment [99]. Intravenous polyclonal immunoglobulins therapy
combined with steroids improved hypoxia and reduced hospital
length-of-stay in severe COVID-19 patients [100]; an ongoing multi-
center RCT will verify these effects. Several non-randomized trials
using different blood purification methods reported benefits in
COVID-19; subsequent ongoing trials evaluate the appropriate tim-
ing, dosing and methodology [101]. Summarising, immune dysregu-
lation and ineffective immuno-inflammatory responses are
frequently observed in response to SARS-CoV-2 infection. The use of
immunomodulators has a potential to at least partly remedy these
derangements. However, their safety and impact on the develop-
ment/progress of COVID-19 across patients groups remain unclear
and caution is advised.
6.6. SARS-CoV-2 neutralizing antibodies
In animals, there has been some evidence that neutralizing anti-
bodies (NAbs) are protective against SARS-CoV-2 infection generating
an interest in their potential prophylactic/therapeutic use against
COVID-19. The available NAbs primarily block the glycoprotein that
mediates binding to the RBD of the host ACE2 (RBD) [102]. A recently
isolated S309 antibody was shown to potently neutralize SARS-CoV-
2 and SARS-CoV-2/SARS-CoV pseudoviruses by engaging the RBD of
the S glycoprotein [103]. Several trials evaluate the convalescent
plasma and anti-spike antibodies (LY-CoV555, REGN-COV2, JS016,
TY027, CT-P59, BRII-196, BRII-198 and SCTA01) to neutralize SARS-
CoV-2 attachment and transmission [104]. A novel double, long-
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lescent COVID-19 patients) currently undergoes testing
(NCT04625972); its alleged advantage rests on combining two mAbs
that simultaneously bind to two non-overlapping sites of the virus
spike glycoprotein thus more effectively blocking the SARS-CoV-2/
ACE2 interaction [105]. A critical aspect in a successful use of NAbs is
their administration dose. An interim analysis of a phase 2 trial using
LY-CoV555 NAb demonstrated that only the medium dose appeared
to accelerate the natural decline in the SARS-CoV-2 load in outpa-
tients with mild-to-moderate COVID-19 [106]. Summarizing, SARS-
CoV-2 neutralizing antibody-based therapies possess a useful dou-
ble-benefit potential: they can be applied both therapeutically and
prophylactically.
7. Challenges in planning clinical trials in a pandemic
Previous pandemics outlined the urgent need for evidence to
guide the best treatments. However, pandemics should not simulta-
neously serve as an excuse for lowering scientific standards [107].
Based on statements of the REMAP-CAP investigators (https://www.
remapcap.org) [108], there are several organizational challenges in
the planning/launching of clinical COVID-19 studies given that the
onset and/or epidemiological dynamics of a pandemic are unpredict-
able [109,110]. To at least partly remedy such challenges, the WHO
advised developing “Master Protocols”, especially for high-powered,
multi-center trials to support the generation of high-quality data
(https://www.who.int/blueprint/priority-diseases/key-action/novel-
coronavirus/en/).
One of the key complexities is that the precise nature of the infect-
ing pathogen(s), clinical consequences and suitable interventions
(particularly pathogen-specific) are not known in advance and infer-
ring information from previous pandemics of related origins can be
misleading and dangerous [111]. In the context of SARS-CoV-2/
COVID-19, this accounts for a poorly understood period of the clinical
progression (i.e. from an initial infection to life-threatening respira-
tory infection). It is likely that a proportion of patients presented
with community-acquired pneumonia may feature a less severe phe-
notype, yet remain at risk of rapidly progressing to severe illness.
Patients who require hospital admission but have a less severe illness
are a particularly important group: an early intervention at a
medium-severity illness may prevent progression to the life-threat-
ening phenotype. Additionally, the proposed treatments will likely
elicit differential treatment effects depending on the magnitude of
the illness severity at the time of treatment administration. A range
of scenarios must be anticipated and used to provide guidance
regarding the most appropriate/beneficial response.
7.1. Time-critical generation of evidence
A typical pandemic elicits a high number of cases occurring over a
short period (weeks, months). In the early phase of the COVID-19
pandemic, researchers heavily relied on so-called “real world” data
e.g. from sources such as electronic medical records, patient regis-
tries, reimbursement/claims data or published single center case
series. All of these have an advantage of an ad hoc availability with a
trade-off of data/analytical quality [112] that may ultimately lead to
false conclusions and/or recommendations (e.g. HCQ). Inappropriate
evaluation of the ''real world'' data caused confusion regarding the
alleged preventive benefits of chronic oral anticoagulants [113,114];
a careful methodological insight revealed analytical shortcomings
(e.g. non-comparable research questions, uncertainties of the estima-
tors).
When more traditional clinical trials are considered, one or few
research questions are typically the driver of a prospectively
designed study with a study protocol. The pandemic has taught us
that such trials are possible and lead to valid conclusions. However,we have also learned that they have to be pragmatic - often large and
simple - and only work with an established technical and organiza-
tional infrastructure. The latter includes appropriate responses from
ethical committees and the public as well as hospital authorities. The
often cited major difference between trials that rely on Frequentist
vs. Bayesian statistics are of lesser importance compared to these
points [115]. Table 4 summarizes large randomized controlled trials
that evaluate/evaluated several different treatments in COVID-19
patients.
8. Interaction between clinical and animal research
Design of animal research for translational purposes should be
largely aimed at supporting the preparation and execution of clinical
trials. This should be done by using the entire available pre-clinical
armamentarium including pathomechanistic investigations, prese-
lection of therapeutics, identification of non-and responder sub-
groups, identification and optimization of endpoints. To achieve
desired synergy, such a process requires knowledge on the limita-
tions and advantages of a given model and intricacies of proper study
design that maximally synchronizes with the stringent demands of
the clinical-level research. Especially in a pandemic, such converging
areas should be developed given the pressing need for a rapid under-
standing of COVID-19 and improvement of patient outcomes. Below,
we present investigative areas with the strongest potential for
enhancement of the animal-to-human investigative synergy.
8.1. COVID-19 severity
Both mild and severe COVID-19 phenotypes are instrumental for
adequate pre-clinical testing of preventive and therapeutic strategies.
The currently predominating mild-to-moderate model phenotype
should not be reflexively rejected as inadequate, however, given that
it enables detection of any adverse effects of tested substances. By
employing high lethality of given disease models, a frequent design
feature in critical illnesses, such a design is primarily set toward
observing hypothesized benefits rather than undesired complications
[116,117]. In the current pandemic, a massive number of trial-tested
substances has been registered - a vast majority with a relatively low
patient enrollment. Drug pre-testing performed in mild-to-moderate
COVID-19 models has a strong potential of detecting i) the lack of
efficacy in non-critically ill and ii) undesired adverse effects, thus
sparing patients from unnecessary exposure to ineffective and/or
potentially harmful substances and directing them toward more
promising interventions. HCQ constitutes a prime example (a
detailed coverage of HCQ controversy in COVID-19 elsewhere [118]);
its premature COVID-19 efficacy-hype was recently denied by the
high-quality trials and all animal tests performed to date [38,51,52].
In this context, the already available COVID-19 models could be rap-
idly employed to investigate potential adverse effects of corticoste-
roids - the only recommended anti-COVID-19 treatment. Animal pre-
testing is also relevant as the current costly deluge of trials over-
whelms the medical staff, may cause competition for COVID-19
patients and promotes inferior and/or unethical trial design practices
[119,120]. Once reproducible, severe COVID-19 models are available,
we suggest a multivariate testing across mild, moderate and severe
phenotypes as it has the best potential to advise on the clinical trial
decision-making.
8.2. Cohort targeting
Compared to human trials, animal studies have a strong advan-
tage regarding pre-selection features. Comparative testing can be rel-
atively easily executed in divergent homogeneous cohorts displaying
a desired pre-defined characteristic, e.g. male/female, young/old,
early/late, lung/gastro-intestinal phenotype. In trials, these elements
Table 4
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CRRT: Continuous renal replacement therapy; ICU: Intensive care unit; MV: mechanical ventilation
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relationship powers). Some treatments may elicit contrasting effects
depending on the COVID-19 characteristics and/or type of targeted
patients; a defined pre-clinical cohort-testing will likely provide an
informational groundwork for clinical investigations. Animal cohort
studies can be i) performed before a trial is launched, ii) run parallel
to an ongoing trial to support testing of defined hypotheses (qualified
as impossible and/or unethical in trials) and/or iii) rapidly executed
to confirm/refute observations from ongoing and finished trials. Theemerging evidence underlines the importance of cohort-oriented
research; aged patients are at risk for unfavorable outcomes whereas
females are less prone to the most severe COVID-19 phenotypes
[121]. Such cohort comparisons are relatively easy to reproduce in
animals and frequently match clinical observations. For example,
female mice demonstrated superior resistance to infectious respira-
tory diseases [44,122] while male mice displayed a more pronounced
mortality after SARS-CoV infection [44]. Additionally, transgenic ani-
mals can effectively address the role of comorbidities. For example,
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can be studied in genetically-manipulated mouse models [123].
8.3. Pathophysiological insight
Relevant animal models, either wild-type or genetically manipu-
lated, appear indispensable for investigation of specific SARS-CoV-2-
induced pathomechanisms such as hypercoagulability and immuno-
inflammatory responses (e.g. compartmentalization) associated with
various disease phenotypes. The explorative possibilities should not
be limited to molecular research but also assess physiological
responses (such as respiratory failure [124,125]. Lessons from other
critical care models (e.g. sepsis) must be learnt to avoid simplistic
approaches, e.g. acute care treatments (e.g. fluid resuscitation, anti-
microbials) [126,127] and prospective risk stratification tools [128]
should be routinely employed. COVID-19 models must also feature
disease-characteristic comorbidities to maximally reflect the patho-
mechanisms occurring in patients e.g. obesity-influenza [129],
asthma-influenza [130], stress-sepsis [131]. Such an approach can
better i) elucidate causative relationships between the infection and
a given comorbidity and ii) explore their underlying mechanisms.
COVID-19 models with comorbidities may likely develop more
severe/lethal phenotypes and long-term impairments (e.g. lung fibro-
sis, fatigue, cognitive dysfunctions). Introduction of wild-type micro-
biome and pathobiome into mice could enable investigation of host-
microbiome-SARS-COV-2 interactions [132]. Another refinement are
two-hit models; they typically involve two (simultaneous, sequen-
tial) acute conditions (e.g. trauma/hemorrhage, secondary infections)
and are superior (versus single-hit) in reproducing complex
responses recorded in acute patients [133]. In COVID-19, two-hit
models could effectively recapitulate frequent scenarios of critically-
ill patients developing secondary infections (e.g. hospital-related
pneumonia, fungemia). Several two-hit models helped to unravel
pathways responsible for secondary infection-triggered pathology
and mortality [134] and disclosed training-priming effects to protect
against aggressive infections [135,136].
8.4. Standardization
Standardization of COVID-19 models will enhance reliability and
trust in preclinical findings. While translation of animal data to the
clinic is not ideal, numerous examples of successful replications of pre-
clinical findings in acute clinical care exist [137,138] including medica-
tions [139] and treatment criteria [140]. Modeling standardization has
been already successfully implemented in diabetes [141,142], stroke
[143], epilepsy [144] and sepsis [145]. An even more advanced
improvement would be a creation of international collaborative
COVID-19 preclinical research platforms that simultaneously investi-
gate the most relevant targets/hypotheses. Operation Brain Trauma
Therapy is an example of such a multicenter consortium (drug and bio-
marker screening) in traumatic brain injury [146]. A coordinated multi-
center approach is especially advisable for NHP studies; individual NHP
experiments are poorly powered and already a two-center study
increases the power of size treatment estimate by approximately 40%
without a need for larger sample size [147]. Pre-clinical data obtained
from standardized SARS-CoV-2/COVID-19 studies (based on blinding,
randomization and multi-center approach) will be superior in enhanc-
ing their utility to guide clinical decisions on i) aborting/entering/pro-
gressing of experimental substances in clinical trials, ii) directing focus
to specific patient cohorts for both benefits and harm, iii) elucidating
specific pathophysiological phenomena, and others.
8.5. Investigating emerging SARS-CoV-2 mutations
It was initially assumed that vaccines would likely match all circu-
lating variants [148], however, the newest non-peer reviewedfindings on SARS-CoV-2 mutations question that assumption. New
variants emerging in Denmark (mink-human infections) with the
D796H and ΔH69/V70 spike mutations resulted in a markedly lower
sensitivity/recognition of the virus by convalescent patient sera
[149]. The deletion ΔH69/V70 is also present in the rapidly spreading
UK variant; it shares the mutation N501Y with the South-African and
the Brazilian variants and the experimentally mouse-adapted SARS-
CoV-2 virus [7]. The two latter variants and the Japanese variant
share the E484K mutation that appear to render them more infective
and partly resistant to neutralizing antibodies (preprinted studies:
[150152]). Emergence of the new SARS-CoV-2 variants creates a
potential investigative niche for animal models; despite obvious
interspecies differences, they could be utilized to test whether the
emerging mutations result in an altered replication, transmissibility,
infectiousness and severity of the infection [153155]. Interestingly,
the serial lung-based passage of SARS-CoV2 generated a mouse-
adapted strain bearing N501Y mutation resembling the above-men-
tioned human variants [8]. Immunized animals can also serve as a
rapid verification platform for vaccination efficacy, i.e., whether or
not the acquired immunity following the use of approved and/or
emerging vaccines remains protective independently of the muta-
tions. This is particularly important, because the consequences of the
mutations were mainly analyzed regarding the reactivity of antibod-
ies from convalescent plasma and vaccinated subjects while the T-
cell immunity and/or global protective immunity were not assessed.
9. Synthesis
COVID-19 pandemic has revealed the limitations of rapidly
designed studies and confusion caused by unreliable data. Yet, a med-
ical threat of this magnitude requires immediate actions. Given this
incongruity, any proposed priorities must balance the need for a
rapid but high-quality response.
9.1. Challenges in animal research
A rapid development of informative animal models appear crucial
in any pandemic. However, such a process should not equal a ram-
pant generation of publishable but low-quality models.
Priority 1: Rapid and consensus model selection. A major focus
should be on a rapid consensus selection and use of high-quality
modeling studies reflecting the largest possible array of clinical dis-
ease scenarios and that are relatively easily reproducible by special-
ized pre-clinical research centers. Pre-clinical work with any highly
infectious pathogen causes various technical impediments and only a
limited number of centers (academic, non-profit, commercial) are
capable of overcoming them. Such impediments delay any develop-
mental process and limit possible options.
Priority 2: Promotion of expert networks and data sharing. It
appears beneficial to promote establishment of pre-clinical networks
of expert-consortia with resources enabling a rapid launch of
research whenever required. Such consortia should combine aca-
demic, non-profit and for-profit research centers and be authorized
to rapidly and consensually share information. A formalized collabo-
rative format will exploit available synergies and lead to develop-
ment of rigorous and reproducible animal models, which can be then
quickly implemented for investigative purposes.
Priority 3: Safeguarding stable funding and ethical approval.
Given the fact that existing expert consortia may best allow for timely
launch of animal model studies, a consensus public funding and ethi-
cal approval (across the entire spectrum of severity) should be rap-
idly obtainable for respective expert-institutions. We propose that
the respective national government funding agencies and ethical
committees have consensually prepared contingency plans allowing
a rapid and synchronized launch of the designated pre-clinical con-
sortia.
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While multiple potential biological targets may be known (or
inferred), classic drug development is delayed in a fluctuating pan-
demic and the presence of virulent pathogens. A global medical crisis
limits implementation of state-of-the-art designs and not all avail-
able drug candidates can be simultaneously tested.
Priority 1. Judicious selection of therapeutics for initial testing. It is
most efficient to use existing, approved substances whose efficacy,
risks are known from other indications, and from which a therapeutic
benefit in COVID-19 (or any future emergency disease) can be
assumed. Experimental substances may potentially offer excellent
treatment benefits but should be viewed as secondary testing choices
due to a protracted safety/efficacy testing process and high risk of
failure.
Priority 2. Reliance on high-quality multicenter pragmatic RCTs.
Most of the available SARS-CoV-2/COVID-19 evidence stems from
low-quality studies. This diverse non-RCT data segment, although
attractive given its simple design and relatively rapid data genera-
tion, typically provides unreliable findings that may provoke errone-
ous changes in treatment guidelines. High-quality RCTs should be
preferred given that despite delay, they provide the most reliable evi-
dence of treatment efficacy, based on which lasting treatment recom-
mendations can be formed.
Priority 3: Separation of patients based on their phenotypic char-
acteristics. COVID-19 has multifaceted presentation and accurate
characterization of various disease phenotypes is central for selection
of adequate therapies (e.g. with immunomodulators). Such a cohort
selection allows i) precise trial enrollment of defined patient types
and ii) reverse-translation of the specific subgroups into respective
animal cohorts for further characterization and testing of therapeu-
tics. Previous trial failures (e.g. in sepsis) imply that such phenotypic
separation is pivotal for the development of individualized interven-
tions.
10. Outstanding questions
Using all available tools, scientists and physicians share an
accountability to understand pathophysiology of the diseases they
combat to maximize the efficacy of treatments and minimize adverse
effects. In the translational research context, the current pandemic
provokes several questions aimed at operationalization of the above-
formulated priorities:
1 How to most effectively facilitate (fiscally, ethically) and stream-
line the development of animal models so they achieve a maximal
fidelity to the clinical COVID-19 presentations?
2 Which elements of the already known evidence should be priori-
tized for bidirectional verification between animal and clinical
studies to enhance understanding of COVID-19 pathophysiology?
3 How to organize, coordinate and optimize global research-
exchange networks amalgamating both pre-clinical and clinical
evidence in a pandemic?
4 How to effectively promote and facilitate preference for advanced
multi-center RCTs over proliferating low-quality trials?
11. Search strategy and selection criteria
First, panels of 23 authors, selected based on their expertise, cre-
ated individual review chapters/sections/tables. Second, each draft
was critically reviewed by all other authors. Third, all authors revised
their drafts based on the received feedback and carried out a final
update to include all most recent relevant studies published during
the writing of the manuscript. The first and corresponding authors
conducted the final assembly of the reviewed chapters. To identifythe relevant information, the authors searched PubMed and/or Med-
line for articles published in English by December 2020, using a panel
of search terms and/or combinations thereof, always including one of
the following terms: ''SARS-CoV-2'', ''COVID-19'', ''MERS-CoV'',
“SARS-CoV”, ''SARS-CoV-1'', ''coronavirus''. Search of medRxiv/bio-
Rxiv was performed to identify and monitor progress of potentially
relevant publications but referencing to publications without peer-
review was kept to minimum and only when necessary (e.g. in the
Testing of emerging SARS-CoV-2 mutations section).12. Contributors
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